UK Medicines Information
olaparib (Lynparza®) accepted for use within NHSScotland
Information type:
Drug best practice guidance
Source:
Scottish Medicines Consortium
Specialities:
Cancers | Obstetrics and gynaecology
Summary
The SMC recommends olaparib for maintenance treatment of adults with advanced (FIGO stages III and IV) BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer responded (complete or partial) to first-line platinum-based chemotherapy.
UKMi comment
Similarly, NICE has also recommended olaparib for this indication within the Cancer Drugs Fund.
Related links:
NICE TA598